Financial Contrast: PharmaCyte Biotech (OTCMKTS:PMCBD) and Protalix BioTherapeutics (NYSE:PLX)

PharmaCyte Biotech (OTCMKTS:PMCBD) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for PharmaCyte Biotech and Protalix BioTherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	0.00
Protalix BioTherapeutics	0	0	1	0	3.00

Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 874.03%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than PharmaCyte Biotech.

Profitability

This table compares PharmaCyte Biotech and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Valuation & Earnings

This table compares PharmaCyte Biotech and Protalix BioTherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Protalix BioTherapeutics	$59.76 million	2.05	$8.31 million	$0.04	38.50

Protalix BioTherapeutics has higher revenue and earnings than PharmaCyte Biotech.

Insider and Institutional Ownership

0.0% of PharmaCyte Biotech shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

PharmaCyte Biotech has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500.

Summary

Protalix BioTherapeutics beats PharmaCyte Biotech on 9 of the 11 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.